Abstract:CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) reportedly stabilizes programmed death-ligand 1 (PD-L1) and enhances the efficacy of immunotherapy. However, correlations between CMTM6 expression and the immune microenvironment and its prognostic value remain unknown in a variety of tumors. CMTM6 expression data were obtained from The Cancer Genome Atlas (TCGA) for 33 cancer types classified into high and low expression subgroups according to the median CMTM6 expression value. Pan-cancer analysis of CMTM6 protein expression in 20 tumor types was performed using a cohort from the Human Protein Atlas (HPA). PD-L1 protein expression data were obtained from The Cancer Proteome Atlas (TCPA) for 32 cancer types. Frequencies of CMTM6 copy number alterations and mutations were analyzed using cBioPortal. MANTIS was employed to estimate microsatellite instability in the TCGA cohort. CIBERSORT and the ESTIMATE algorithm were applied to estimate the relative fractions of infiltrating immune cell types and immune scores, respectively. Kaplan–Meier survival curve analysis was performed to assess the pan-cancer prognostic value of CMTM6.CMTM6 is heterogeneously expressed in diverse cancers. Further, the results revealed low CMTM6 mutation frequencies in multiple cancers. Among them, CMTM6 mutation frequency was the highest in uterine cancer. Additionally, CMTM6 expression was related to PD-L1 protein expression in breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, glioblastoma multiforme (GBM), head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma, sarcoma (SARC), stomach adenocarcinoma, and uterine carcinosarcoma. Increased CMTM6 expression may be associated with increased infiltration of neutrophils in some types of cancer. Finally, pan-cancer analysis indicated that CMTM6 expression was closely related to overall survival in adrenocortical carcinoma, GBM, acute myeloid leukemia, liver hepatocellular carcinoma, mesothelioma, SARC, thymoma, and uveal melanoma. Taken together, these findings highlight that CMTM6 plays an important role in the tumor immune microenvironment, and CMTM6 has been identified to have prognostic value in some types of cancers. Thus, CMTM6 is a potential target for cancer immunotherapy and effective prognostic biomarker.

Cancer Research Advance in CKLF-like MARVEL Transmembrane Domain Containing Member Family (Review).

Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer

Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors

Research advances in CKLF-like MARVEL transmembrane domain containing member 5]

CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value

Chemokine-Like Factor-Like Marvel Transmembrane Domain-Containing Family In Hepatocellular Carcinoma: Latest Advances

Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.

Research Advances in Chemokine-like Factor Super Family Member 8

Chemokine-like Factor-Like MARVEL Transmembrane Domain-Containing Family in Autoimmune Diseases

Function of CMTM2 in Male Reproductive System

Expression of CMTM3 and CMTM5 in clear cell renal cell carcinoma and its significance

CMTM4 is Frequently Downregulated and Functions As a Tumour Suppressor in Clear Cell Renal Cell Carcinoma

CMTM1_v17 is a novel potential therapeutic target in breast cancer.

Cmtm3, Located At The Critical Tumor Suppressor Locus 16q22.1, Is Silenced By Cpg Methylation In Carcinomas And Inhibits Tumor Cell Growth Through Inducing Apoptosis

Data from <i>CMTM3</i>, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis

Research advances of MAL family members in tumorigenesis and tumor progression (Review)

Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia

CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways

Prognostic Implications of Pan-cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment

Research Advances in the Role of the Tropomyosin Family in Cancer

CMTM4 Inhibits Cell Proliferation and Migration Via AKT, ERK1/2, and STAT3 Pathway in Colorectal Cancer